Background: Acquired factor VIII inhibitor is an antibody formed against FVIII and seen in patients without FVIII replacement therapy. This entity has been associated with both autoimmune disease and infections. Case Study: We report the case of a 65-year-old man with dermatomyositis who presented with a bleeding episode following venipuncture and hematuria. His coagulation parameters were followed as well as the inhibitor level. His acquired FVIII inhibitor was managed successfully with rituximab. Conclusion: Our patient’s bleeding episodes resolved and the inhibitor level was undetectable after 12 months. This is the first case of acquired FVIII inhibitor in association with dermatomyositis.

Keywords:
Dermatomyositis, Factor VIII, Inhibitor
1.
Green D, Lechner K: A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981;45:200–203.
2.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A: Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21–35.
3.
Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR: Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004;10:174–178.
4.
Hay CR, Negrier C, Ludlam CA: The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997;78:1463–1467.
5.
Shaffer LG, Phillips MD: Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med 1997;127:206–209.
6.
Lafferty TE, Smith B, Schuster SJ, Dehoratius RJ: Treatment of acquired factor VIII inhibitor using intravenous Immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:775–778.
7.
Fuente B, Panek S, Hoyer LW: The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor. Br J Haematol 1985;59:127–131.
8.
Al-Ismail SAD, Parry DH, Moisey CU, Bloom AL: Factor VIII inhibitor and bronchogenic carcinoma. Thromb Haemost 1979;41:291–295.
9.
Castaldi PA, Penny R: A macroglobulin with inhibitory activity against coagulation factor VIII. Blood 1970;35:370–376.
10.
Dentale N, Fulgaro C, Guerra L, Fasulo G, Mazzetti M, Fabbri C: Acquisition of factor VIII after acute hepatitis C virus infection. Blood 1997;90:3233–3234.
11.
O’Reiley RA, Hamilton RD: Acquired haemophilia, meningioma and diphenylhydantoin therapy. J Neurosurg 1980;53:600–605.
12.
Cohen AJ, Kessler CM: Acquired inhibitors. Baillieres Clin Haematol 1996;9:331–354.
13.
Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkin MD: Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992;89:3795–3799.
14.
Sohngen D, Specker C, Bach D, Kuntz BME, Burk M, Aul C, Kobbe G, Heyll A, Hollmig KA, Schneider W: Acquired factor VIII inhibitors in nonhemophiliac patients. Ann Haematol 1997;74:89–93.
15.
Collins PW: Treatment of acquired hemophilia A. J Thromb Haemost 2007;5:893–900.
16.
Spero JA, Lewis JH, Hasiba U: Corticosteroid therapy for acquired FVIII: C inhibitors. Br J Haematol 1981;48:635–642.
17.
Dykes AC, Walker ID, Lowe GD, Tait RC: Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 2001;7:160–163.
18.
Green D, Rademaker AW, Briet E: A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993;70:753–757.
19.
Stasi R, Pagano A, Stipa E, Amadori S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952–957.
20.
Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827–3834.
21.
Holme PA, Brosstad F, Tjonnfjord GE: Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005;11:510–515.
22.
Wiestner A, Cho HJ, Asch AS, Michelis M, Zeller JA, Peerschke EI, Weksler BB, Schechter GP: Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426–3428.
23.
Kain S, Copeland TS, Leahy MF: Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (ritiximab). Br J Haematol 2002;119:578.
24.
Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, Wiestner A, Schechter GP: Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005;11:13–19.
25.
Freim Wahl SG, Folvik MR, Torp SH: Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 2007;26:68–73.
26.
Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I: Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307–1312.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.